Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)
Avalo Therapeutics' (AVTX) quarterly Intangibles came in at $38000.0 in Q4 2021, down 97.6% YoY from $1.6 million in Q4 2020, and down 87.5% on a QoQ basis from $304000.0 in Q3 2021.
Avalo Therapeutics (AVTX) Intangibles (2017 - 2021) Analysis & Trends
Avalo Therapeutics (AVTX) has 5 years of Intangibles data on file, last reported at $38000.0 in Q4 2021.
- Quarterly Intangibles fell 97.6% year-over-year to $38000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $38000.0 (down 97.6% YoY) and the FY2021 annual result came in at $38000.0, down 97.6% from the prior year.
- Intangibles fell to $38000.0 in Q4 2021, from $304000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $33.1 million in Q1 2018 to a low of $38000.0 in Q4 2021.
- A 5-year average of $10.9 million and a median of $2.3 million in 2020 frame the typical range for Intangibles.
- The widest YoY moves for Intangibles: up 29.0% in 2021, down 97.6% in 2021.
- Tracing AVTX's Intangibles over 5 years: stood at $17.7 million in 2017, then tumbled by 78.68% to $3.8 million in 2018, then sank by 35.57% to $2.4 million in 2019, then sank by 34.67% to $1.6 million in 2020, then sank by 97.6% to $38000.0 in 2021.
- The last three Intangibles figures came in at $38000.0 (Q4 2021), $304000.0 (Q3 2021), and $732000.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 38,000.00 |
| Sep 30, 2021 | 304,000.00 |
| Jun 30, 2021 | 732,000.00 |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 1.59 Mn |
| Sep 30, 2020 | 1.89 Mn |
| Jun 30, 2020 | 2.29 Mn |
| Mar 31, 2020 | 900,000.00 |
| Dec 31, 2019 | 2.43 Mn |
| Sep 30, 2019 | 26.60 Mn |
| Jun 30, 2019 | 27.63 Mn |
| Mar 31, 2019 | 1.40 Mn |
| Dec 31, 2018 | 3.77 Mn |
| Sep 30, 2018 | 32.46 Mn |
| Jun 30, 2018 | 32.00 Mn |
| Mar 31, 2018 | 33.10 Mn |
| Dec 31, 2017 | 17.66 Mn |